The acquisition of Inspirata’s digital pathology technology and its team will help Fujifilm to expand its Synapse Enterprise Imaging offering to enhance care delivery for oncology patients and provider

misael-moreno-Rl9bIWKCVF0-unsplash

Fujifilm to acquire Inspirata Dynamyx digital pathology. (Credit: Misael Moreno on Unsplash)

Fujifilm has agreed to acquire the US-based cancer diagnostics solution provider Inspirata’s digital pathology business for an undisclosed sum.

Under the terms of the agreement, the Japanese company will acquire Inspirata Dynamyx digital pathology, together with its employees and customers.

With the addition of Inspirata’s digital pathology unit, Fujifilm is enabled to expand its Synapse Enterprise Imaging portfolio of healthcare IT solutions.

Synapse integrates pathology images and data into a healthcare organisation’s electronic health record system to streamline care delivery for oncology patients and provider teams.

The acquisition builds on Fujifilm’s existing partnership with Inspirata and marks the company’s full-scale entry into the digital pathology market.

It is expected to be completed in early 2023, subject to certain customary closing conditions.

Fujifilm representative director, president and CEO Teiichi Goto said: “Acquiring Inspirata’s digital pathology business allows Fujifilm to be an even stronger healthcare partner – bridging a technological gap between pathology, radiology and oncology to facilitate a more collaborative approach to care delivery across the enterprise.

“We’re thrilled to welcome Inspirata’s digital pathology experts to Fujifilm’s growing medical informatics business, along with their renowned global customer base, as together we work to drive the digitization and advancement of healthcare.”

Digital pathology refers to the digitisation of pathology slides to enable software-powered visualisation analysis of a specimen rather than using microscopic slides.

According to Fujifilm, the digital pathology market is mostly unpenetrated, with more than 80% of healthcare organisations currently running on analogue systems.

Dynamyx is an open, vendor-agnostic, end-to-end digital pathology solution that has been approved by regulatory agencies in the US, Canada, Europe, and the UK.

It uses whole slide images from multiple scanning vendors to create an easier path for pathology labs to benefit from digitisation.

Digitisation enables faster patient results, centralised imaging records, and enterprise access to images for all clinicians.

Dynamyx will become a part of Fujifilm’s Synapse Enterprise Imaging portfolio and will be installed in medical facilities that handle large volumes of pathological images.

Fujifilm Healthcare Americas will own Dynamyx technology, lead its ongoing development and engineering in the US, and will license it to other regions.

Fujifilm Healthcare Americas president and CEO Henry Izawa said: “The rising number of cancer cases and the demonstrated benefits of digital pathology are fuelling significant demand and market growth in the hospital and pharmaceutical industries http://webbanki.ru/zaim-na-kartu .

“These evolving clinical needs fuel Fujifilm’s investment and innovation in the digital revolution, and we look forward to introducing Dynamyx and its host of unique features and benefits to our Synapse customers and prospects as we strive to enable more efficient medical diagnosis and high-quality care.”

Earlier this month, Fujifilm invested in the US-contract research organisation (CRO) PhenoVista Biosciences, which provides customised imaging-based assay services.